Skip to main content
GSK
NYSE Life Sciences

US FDA Approves GSK's Utebzi, First Oral Carbapenem for Complicated UTIs

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$52.585
Mkt Cap
$104.917B
52W Low
$35.45
52W High
$61.695
52W Position info
48% above low
Off High info
15% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

GSK sits 48% above its 52-week low of $35.45.

Summary

GSK announced FDA approval for Utebzi, the first and only oral carbapenem antibiotic for complicated urinary tract infections, offering a new outpatient treatment option.


Key Events · Product Development and Regulatory · GSK

  • FDA Approval for Utebzi

    The US FDA has approved Utebzi (tebipenem pivoxil), an oral antibiotic, for the treatment of complicated urinary tract infections (cUTIs) in adults.

  • First Oral Carbapenem

    Utebzi is the first and only oral carbapenem antibiotic approved in the US, offering an oral alternative to previously intravenous-only carbapenem treatments.

  • Addresses Unmet Medical Need

    The drug targets over 3 million annual cUTI cases in the US, including those caused by multidrug-resistant pathogens, potentially reducing hospital resource use.

  • Partnership with Spero Therapeutics

    This approval is a result of GSK's exclusive global licensing agreement (excluding select Asian territories) with Spero Therapeutics.


Analysis · GSK · Life Sciences

The FDA approval of Utebzi provides a critical new oral treatment option for complicated urinary tract infections (cUTIs), including those caused by multidrug-resistant pathogens. This is significant as carbapenems were previously only available intravenously, potentially reducing hospital stays and improving patient quality of life for over 3 million annual US cases. This strengthens GSK's anti-infectives portfolio and addresses a substantial unmet medical need.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, GSK was trading at $52.59 on NYSE in the Life Sciences sector, with a market capitalization of approximately $104.9B. The 52-week trading range was $35.45 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GSK - Latest Insights

GSK
Nov 17, 2026, 1:26 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $49.51
Real-time Price: $47.96 info
Change: -$1.55 (-3%) info
Market Cap: $95.854B info
GSK
Oct 28, 2026, 11:45 AM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $48.75
Real-time Price: $47.96 info
Change: -$0.7949 (-2%) info
Market Cap: $95.854B info
GSK
Oct 28, 2026, 10:45 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $49.08
Real-time Price: $47.96 info
Change: -$1.12 (-2%) info
Market Cap: $95.854B info
GSK
Oct 28, 2026, 3:42 AM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $51.20
Real-time Price: $47.96 info
Change: -$3.24 (-6%) info
Market Cap: $95.854B info
GSK
Oct 26, 2026, 12:16 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $51.12
Real-time Price: $47.96 info
Change: -$3.16 (-6%) info
Market Cap: $95.854B info